328:F MEIRAGTX HLDGSDL-0000388

EUR 4.30 0.00 0
Icon

MEIRAGTX HLDGSDL-0000388 (328:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 4.30

0.00 (0.00)%

EUR 0.34B

0.01M

N/A

N/A

Icon

328:F

MEIRAGTX HLDGSDL-0000388 (EUR)
COMMON STOCK | F
EUR 4.30
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.34B

N/A

EUR 4.30

MEIRAGTX HLDGSDL-0000388 (328:F) Stock Forecast

N/A

Based on the MEIRAGTX HLDGSDL-0000388 stock forecast from 0 analysts, the average analyst target price for MEIRAGTX HLDGSDL-0000388 is not available over the next 12 months. MEIRAGTX HLDGSDL-0000388’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MEIRAGTX HLDGSDL-0000388 is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, MEIRAGTX HLDGSDL-0000388’s stock price was EUR 4.30. MEIRAGTX HLDGSDL-0000388’s stock price has changed by -6.11% over the past week, -25.86% over the past month and -8.12% over the last year.

No recent analyst target price found for MEIRAGTX HLDGSDL-0000388
No recent average analyst rating found for MEIRAGTX HLDGSDL-0000388

Company Overview MEIRAGTX HLDGSDL-0000388

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegene...Read More

https://meiragtx.com

450 East 29th Street, New York, NY, United States, 10016

419

December

EUR

Germany

Adjusted Closing Price for MEIRAGTX HLDGSDL-0000388 (328:F)

Loading...

Unadjusted Closing Price for MEIRAGTX HLDGSDL-0000388 (328:F)

Loading...

Share Trading Volume for MEIRAGTX HLDGSDL-0000388 Shares

Loading...

Compare Performance of MEIRAGTX HLDGSDL-0000388 Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 328:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To MEIRAGTX HLDGSDL-0000388 (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S 0.00 (0.00%) EUR525.74B 45.80 4.49

ETFs Containing 328

Symbol Name 328's Weight Expense Ratio Price(Change) Market Cap
HKDU:SW
UBS(Lux)Fund Solutions â€.. 11.39 % 0.00 % 0.00 (0.00%) EUR0.27B

Frequently Asked Questions About MEIRAGTX HLDGSDL-0000388 (328:F) Stock

Stock Target Advisor's fundamental analysis for MEIRAGTX HLDGSDL-0000388's stock is Neutral.

Unfortunately we do not have enough data on 328:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 328:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on 328:F's stock to indicate if its overvalued.

The last closing price of 328:F's stock was EUR 4.30.

The most recent market capitalization for 328:F is EUR 0.34B.

Unfortunately we do not have enough analyst data on 328:F's stock to indicate whether its price will go up or not.

Following are ETFs with the highest allocation to MEIRAGTX HLDGSDL-0000388's stock :

HKDU:SW

As per our most recent records MEIRAGTX HLDGSDL-0000388 has 419 Employees.

MEIRAGTX HLDGSDL-0000388's registered address is 450 East 29th Street, New York, NY, United States, 10016. You can get more information about it from MEIRAGTX HLDGSDL-0000388's website at https://meiragtx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...